Abbott bolsters diagnostics portfolio with up to $23 billion buyout of Exact Sciences
Abbott will pay $105 per share, a 21.8% premium, to acquire Exact Sciences and expand its presence in the $60 billion U.S. cancer diagnostics market.
- Abbott announced it will acquire Exact Sciences for up to $23 billion, strengthening its diagnostics business with Exact Sciences' colorectal cancer test Cologuard.
- As part of the agreement, Exact Sciences shareholders will receive $105 per share, representing a 21.8% premium over the last closing price.
- The deal, expected to close in Q2 2026 after shareholder approval, will make Exact Sciences a subsidiary of Abbott and boost Abbott's diagnostics sales to over $12 billion annually.
35 Articles
35 Articles
Abbott Breaks into Lucrative Cancer Screening Market with $21 Billion Exact Sciences Purchase
Suburban Chicago is a long way from Britain, but they’re still calling it a bloody good deal. Illinois-based healthcare giant Abbott Laboratories said Thursday that it agreed to buy cancer-screening specialist Exact Sciences and its breakthrough blood test for $21 billion. Match Made in Lab Heaven Founded in 1880s Chicago by a pharmacist with a talent for formulating medicines from plants and herbs, Abbott is now a multinational healthcare giant…
Abbott to acquire Madison-based Exact Sciences for $23 billion
MADISON, Wis. — Abbott agrees to acquire Exact Sciences for an estimated value up to $23 billion. The acquisition will include Exact Sciences’ cancer screening product lines Cologuard®, Oncotype DX®, and Cancerguard™, and possibly the absorption of Exact Sciences’ estimated $1.8 billion of net debt. The Madison-based Exact Sciences focuses on the early detection of cancer and personalized treatments through cancer screening, precision oncology a…
Why Exact Sciences Stock Surged Today
Key PointsAbbott made a takeover offer for Exact Sciences.The two companies want to team up to combat cancer.10 stocks we like better than Exact Sciences › Shares of Exact Sciences (NASDAQ: EXAS) climbed on Thursday after the medical diagnostics specialist agreed to be acquired by Abbott (NYSE: ABT) for $21 billion. As of 2:30 p.m. EST, Exact Sciences' stock price was up more than 17%.Where to invest $1,000 right now? Our analyst team just revea…
Coverage Details
Bias Distribution
- 74% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium














